Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4864551
Max Phase: Preclinical
Molecular Formula: C45H67NO9
Molecular Weight: 766.03
Molecule Type: Unknown
Associated Items:
ID: ALA4864551
Max Phase: Preclinical
Molecular Formula: C45H67NO9
Molecular Weight: 766.03
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@H]1[C@@H](O[C@@H]2CC[C@@]3(C)[C@@H](C2)C[C@@H](O)[C@@H]2[C@@H]3C[C@H](O)[C@]3(C)[C@@H]([C@H](C)CCCOC(=O)c4cccnc4)CC[C@@H]23)O[C@@H]2O[C@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3
Standard InChI: InChI=1S/C45H67NO9/c1-25(9-8-20-50-39(49)28-10-7-19-46-24-28)31-13-14-34-38-35(23-37(48)44(31,34)6)42(4)17-15-30(21-29(42)22-36(38)47)51-40-27(3)33-12-11-26(2)32-16-18-43(5)53-41(52-40)45(32,33)55-54-43/h7,10,19,24-27,29-38,40-41,47-48H,8-9,11-18,20-23H2,1-6H3/t25-,26-,27-,29+,30-,31-,32+,33+,34+,35+,36-,37+,38+,40+,41-,42+,43+,44-,45-/m1/s1
Standard InChI Key: KKLKZVMYJGFWQG-RMLZPHKNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 766.03 | Molecular Weight (Monoisotopic): 765.4816 | AlogP: 7.85 | #Rotatable Bonds: 8 |
Polar Surface Area: 125.80 | Molecular Species: NEUTRAL | HBA: 10 | HBD: 2 |
#RO5 Violations: 2 | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: | CX Basic pKa: 3.24 | CX LogP: 7.64 | CX LogD: 7.64 |
Aromatic Rings: 1 | Heavy Atoms: 55 | QED Weighted: 0.12 | Np Likeness Score: 2.52 |
1. Zou X, Liu C, Li C, Fu R, Xu W, Bian H, Dong X, Zhao X, Xu Z, Zhang J, Shen Z.. (2021) Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents., 225 [PMID:34399390] [10.1016/j.ejmech.2021.113754] |
Source(1):